Abstract:The discovery of hypoxia-inducible factor-1 has led to a rapidly increasing understanding of the molecular mechanism of tumor hypoxia in the past two decades. Today it is generally accepted that HIF-1 plays a pivotal role in the cellular response to tumor hypoxia which represents a major obstacle to the success of radiotherapy and chemotherapy. Meanwhile, many details involved in the expression, accumulation and transactivation of HIF-1 have been well elucidated. Targeting HIF-1 has become a novel and efficient strategy for cancer therapy and a number of agents have been developed aiming to suppress HIF-1. This review will concisely introduce the general knowledge on the molecular biology of HIF-1 and possible targets along the HIF-1 pathway. Moreover, a number of compounds reported with anti-HIF-1 activity are included and mainly classified as direct and indirect inhibitors based on their different modes of action. While direct HIF-1 inhibitors prevent HIF-1 from transactivation, DNA binding and subsequently initiating transcriptional activity, indirect HIF-1 inhibitors generally block the transcription or translation of HIF-1α or promote the degradation of HIF-1α protein. According to different structural features, direct HIF-1 inhibitors are divided into several groups: polyamides, quinols and naphthoquinone spiroketal analogues, shikonin derivatives, epidithiodiketopiperazines, and two representative drugs: echinomycin and bortezomib. In the same way, indirect inhibitors comprise the following classes: polyphenols, benzoazaheterocycles, rapamycins, camptothecins, geldanamycins, (aryloxyacetylamino)benzoic acid analogues, 2-methoxyestradiol and analogues, hydroxamic acid compounds and others. The rest with mechanism still not so clear would also be listed and introduced, with an emphasis on the marinederived natural products. The in vitro and/or in vivo activities of these compounds and their mechanisms of HIF-1 inhibition would be discussed and the SARs of unique structural types of HIF-1 inhibitors will be briefly concluded.

Digoxin and Other Cardiac Glycosides Inhibit HIF-1α Synthesis and Block Tumor Growth

Digoxin Inhibits Retinal Ischemia-Induced HIF-1alpha Expression and Ocular Neovascularization.

Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation

Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation

Hypoxia Inducible Factor-1 alpha: A New Anticancer Drug Target

Na+/K+-ATPase-Targeted Cytotoxicity of (+)-Digoxin and Several Semisynthetic Derivatives

Digoxin and its Na+/K+-ATPase-targeted actions on cardiovascular diseases and cancer

Multifaceted Anti-Colorectal Tumor Effect of Digoxin on HCT8 and SW620 Cells in Vitro

Effect of Digoxin on Proliferation and Apoptosis of Human Prostate Cancer Cell

Inhibitors of Hypoxia-Inducible Factor 1 Block Breast Cancer Metastatic Niche Formation and Lung Metastasis

Anticancer Activity of Natural Flavonoids: Inhibition of HIF-1α Signaling Pathway

Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1α

Negative regulation of thyroid adenoma-associated protein (THADA) in the cardiac glycoside-induced anti-cancer effect

Cardiac glycosides inhibit cancer through Na/K-ATPase-dependent cell death induction.

Cancer Therapeutic Agents Targeting Hypoxia-Inducible Factor-1

Cardiac Glycosides Inhibit Proliferation And Induce Apoptosis Of Human Hematological Malignant Cells

Digoxin Inhibits Pdgf-Bb-Induced Vsmc Proliferation And Migration Through An Increase In Ilk Signaling And Attenuates Neointima Formation Following Carotid Injury

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Identification of small molecule compounds that inhibit the HIF-1 signaling pathway

Targeting HIF-1 for cancer therapy

Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy